Wealth Enhancement Advisory Services’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $117M | Buy |
576,543
+36,002
| +7% | +$7.75M | 0.2% | 95 |
|
|
2026
Q1 | $92.7M | Sell |
540,541
-96,169
| -15% | -$21.3M | 0.19% | 102 |
|
|
2025
Q4 | $143M | Buy |
636,710
+66,720
| +12% | +$15.2M | 0.19% | 92 |
|
|
2025
Q3 | $133M | Buy |
569,990
+15,340
| +3% | +$3.12M | 0.2% | 98 |
|
|
2025
Q2 | $105M | Buy |
554,650
+18,200
| +3% | +$3.38M | 0.17% | 116 |
|
|
2025
Q1 | $112M | Buy |
536,450
+12,085
| +2% | +$2.35M | 0.22% | 89 |
|
|
2024
Q4 | $93.2M | Sell |
524,365
-31,930
| -6% | -$5.87M | 0.18% | 115 |
|
|
2024
Q3 | $110M | Buy |
556,295
+104,454
| +23% | +$19.5M | 0.24% | 81 |
|
|
2024
Q2 | $77.5M | Buy |
451,841
+27,103
| +6% | +$4.49M | 0.18% | 110 |
|
|
2024
Q1 | $77.3M | Buy |
424,738
+32,732
| +8% | +$5.64M | 0.2% | 106 |
|
|
2023
Q4 | $60.7M | Sell |
392,006
-49,324
| -11% | -$7.19M | 0.18% | 126 |
|
|
2023
Q3 | $65.8M | Buy |
441,330
+413,330
| +1,476% | +$60.7M | 0.22% | 102 |
|
|
2023
Q2 | $3.77M | Sell |
28,000
-3,912
| -12% | -$574K | 0.04% | 147 |
|
|
2023
Q1 | $5.09M | Buy |
+31,912
| New | +$4.88M | 0.06% | 133 |
|
|
2022
Q4 | – | Sell |
-44,537
| Closed | -$6.18M | – | 317 |
|
|
2022
Q3 | $6.18M | Buy |
44,537
+30,880
| +226% | +$4.43M | 0.09% | 106 |
|
|
2022
Q2 | $2.09M | Buy |
13,657
+12,072
| +762% | +$1.84M | 0.03% | 200 |
|
|
2022
Q1 | $257K | Sell |
1,585
-317
| -17% | -$46K | ﹤0.01% | 294 |
|
|
2021
Q4 | $260K | Sell |
1,902
-3,546
| -65% | -$419K | ﹤0.01% | 280 |
|
|
2021
Q3 | $596K | Buy |
5,448
+3
| +0.1% | +$343 | 0.01% | 243 |
|
|
2021
Q2 | $638K | Buy |
5,445
+119
| +2% | +$13.4K | 0.01% | 220 |
|
|
2021
Q1 | $561K | Buy |
5,326
+504
| +10% | +$53.9K | 0.01% | 226 |
|
|
2020
Q4 | $533K | Sell |
4,822
-34,928
| -88% | -$3.36M | 0.01% | 193 |
|
|
2020
Q3 | $3.51M | Buy |
39,750
+5,036
| +15% | +$474K | 0.09% | 79 |
|
|
2020
Q2 | $3.39M | Buy |
34,714
+605
| +2% | +$53.3K | 0.1% | 80 |
|
|
2020
Q1 | $2.82M | Buy |
+34,109
| New | +$2.91M | 0.1% | 88 |
|
|
2019
Q2 | – | Sell |
-21,343
| Closed | -$1.68M | – | 198 |
|
|
2019
Q1 | $1.68M | Buy |
21,343
+4,833
| +29% | +$395K | 0.09% | 90 |
|
|
2018
Q4 | $1.48M | Sell |
16,510
-17,069
| -51% | -$1.5M | 0.09% | 81 |
|
|
2018
Q3 | $2.67M | Sell |
33,579
-8,579
| -20% | -$814K | 0.16% | 46 |
|
|
2018
Q2 | $4.09M | Buy |
42,158
+34,000
| +417% | +$3.32M | 0.25% | 39 |
|
|
2018
Q1 | $752K | Buy |
8,158
+4,180
| +105% | +$459K | 0.05% | 131 |
|
|
2017
Q4 | $399K | Buy |
+3,978
| New | +$375K | 0.03% | 134 |
|
Other funds holding ABBV
Wealth Enhancement Advisory Services's ABBV Position: Q2 2026 in Review
Wealth Enhancement Advisory Services increased its AbbVie (ABBV) stake by 6.7% in Q2 2026, buying an estimated $7.75M and bringing the position to 576,543 shares worth $117M. The position accounts for 0.2% of the portfolio, ranked #95.
Wealth Enhancement Advisory Services first reported a position in ABBV in Q4 2017 and has held it in 31 quarters since. The position peaked at $143M in Q4 2025. 4,218 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Wealth Enhancement Advisory Services held 576,543 shares of AbbVie worth $117M as of Q2 2026.
- Wealth Enhancement Advisory Services bought 36,002 AbbVie shares in Q2 2026, an estimated $7.75M.
- AbbVie made up 0.2% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #95 holding.
- Wealth Enhancement Advisory Services first reported a position in AbbVie in Q4 2017 and has held it in 31 quarters since.
- Wealth Enhancement Advisory Services's AbbVie position peaked at $143M in Q4 2025.
- 4,218 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.